OncoCyte Crecimiento futuro

Future controles de criterios 2/6

Se prevé un crecimiento anual de los beneficios y los ingresos de OncoCyte de 9.9% y 55.1% respectivamente, mientras que el BPA crecerá en un 18.6% al año.

Información clave

9.9%

Tasa de crecimiento de los beneficios

18.6%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	26.4%
Tasa de crecimiento de los ingresos	54.2%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	24 Apr 2024

Actualizaciones recientes sobre el crecimiento futuro

No hay actualizaciones

Recent updates

Previsiones de crecimiento de beneficios e ingresos

LSE:0KCC - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	9	-20	N/A	N/A	1
12/31/2025	6	-20	N/A	N/A	3
12/31/2024	2	-22	N/A	N/A	3
12/31/2023	2	-26	-24	-23	N/A
9/30/2023	1	-22	-29	-28	N/A
6/30/2023	1	-17	-39	-38	N/A
3/31/2023	1	-11	-45	-42	N/A
12/31/2022	1	-19	-50	-46	N/A
9/30/2022	-1	-22	-47	-43	N/A
6/30/2022	0	-34	-46	-43	N/A
3/31/2022	1	-43	-42	-39	N/A
12/31/2021	2	-44	-38	-36	N/A
9/30/2021	5	-35	-37	-35	N/A
6/30/2021	4	-28	-32	-30	N/A
3/31/2021	2	-26	-31	-29	N/A
12/31/2020	1	-30	-27	-26	N/A
9/30/2020	1	-32	-27	-25	N/A
6/30/2020	0	-30	-25	-24	N/A
3/31/2020	0	-26	-21	-20	N/A
12/31/2019	N/A	-22	-21	-20	N/A
9/30/2019	N/A	-19	-17	-17	N/A
6/30/2019	N/A	-17	-15	-14	N/A
3/31/2019	N/A	-16	-16	-16	N/A
12/31/2018	N/A	-16	-12	-12	N/A
9/30/2018	N/A	-15	-13	-13	N/A
6/30/2018	N/A	-19	-14	-14	N/A
3/31/2018	N/A	-18	-13	-13	N/A
12/31/2017	N/A	-19	-13	-13	N/A
9/30/2017	N/A	-19	N/A	-13	N/A
6/30/2017	N/A	-14	N/A	-10	N/A
3/31/2017	N/A	-13	N/A	-9	N/A
12/31/2016	N/A	-11	N/A	-8	N/A
9/30/2016	N/A	-12	N/A	-7	N/A
6/30/2016	N/A	-11	N/A	-7	N/A
3/31/2016	N/A	-10	N/A	-6	N/A
12/31/2015	N/A	-9	N/A	-4	N/A
9/30/2015	N/A	-7	N/A	-3	N/A
6/30/2015	N/A	-5	N/A	-2	N/A
3/31/2015	N/A	-5	N/A	-1	N/A
12/31/2014	N/A	-5	N/A	-1	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que 0KCC siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que 0KCC siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que 0KCC siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (55.1% al año) de 0KCC crezcan más rápidamente que los del mercado UK (3.3% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (55.1% al año) de 0KCC crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de 0KCC se prevé que sea elevada dentro de 3 años.

OncoCyte Crecimiento futuro

Future controles de criterios 2/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

OncoCyte Corporation to Report Q1, 2024 Results on May 15, 2024

OncoCyte Corporation, Annual General Meeting, Jun 28, 2024

OncoCyte Corporation announced that it has received $15.8 million in funding

Broadwood Capital, Inc. Engages with OncoCyte Corporation

OncoCyte Corporation announced that it expects to receive $15.8 million in funding

OncoCyte Corporation announced delayed annual 10-K filing

OncoCyte Corporation announced delayed annual 10-K filing

Oncocyte Corporation Begins FDA Submissions Process for VitaGraft Transplant Assays

OncoCyte Corporation to Report Q3, 2023 Results on Nov 09, 2023

Oncocyte Corporation Announces Vitagraft Kidney Transplant Diagnostic Test Receives Cms Coverage

Oncocyte Corporation Announces Executive Changes

OncoCyte Regains Compliance with Nasdaq Listing Requirements

OncoCyte Corporation to Report Q2, 2023 Results on Aug 10, 2023

Oncocyte Corporation Announces the Publication of New Data Demonstrating Vitagraft Kidney's Novel Ability to Help Physicians Treat Kidney Transplant Patients

Oncocyte Announces 1-For-20 Reverse Stock Split to Regain Compliance with Minimum Bid Price Requirement

Jennifer Levin Carter and John Peter Gutfreund Not to Stand for Re-Election to the Board of Directors of OncoCyte Corporation

OncoCyte Corporation, Annual General Meeting, Jun 23, 2023

OncoCyte Receives Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard

Oncocyte Applies to Transfer the Listing of its Common Stock from The Nasdaq Global Market to The Nasdaq Capital Market

OncoCyte Corporation Announces Reduction of Workforce

High number of new and inexperienced directors

OncoCyte Corporation Announces Executive Changes

Melinda Griffith Notifies Oncocyte Corporation F Her Resignation from the Board, Effective January 1, 2023

OncoCyte Corporation to Report Q3, 2022 Results on Nov 10, 2022

High number of new directors

Oncocyte Corporation Appoints James Liu as Controller and Principal Accounting Officer

High number of new directors

Oncocyte Announces Unanimous Recommendation from the Advisory Panel for Clinical Diagnostic Laboratory Tests on Determarx to CMS

Oncocyte Announces Publication of the Validation of DetermaIO in Predicting Immune Therapy Response in Metastatic Bladder Cancer

Independent Chairman recently bought US$144k worth of stock

OncoCyte Corporation Receives Non-Compliance Letter from Nasdaq

Second quarter 2022 earnings released: US$0.073 loss per share (vs US$0.12 loss in 2Q 2021)

OncoCyte Corporation Appoints Anish John as Chief Financial Officer

OncoCyte Corporation Announces the Appointment of John Peter Gutfreund as Independent Member of its Board of Directors

OncoCyte Corporation to Report Q2, 2022 Results on Aug 10, 2022

High number of new directors

OncoCyte Corporation Announces Resignation of Li Yu as Controller and Principal Accounting Officer

OncoCyte Corporation(NasdaqGM:OCX) dropped from Russell 2000 Dynamic Index

OncoCyte Corporation, Annual General Meeting, Jul 15, 2022

First quarter 2022 earnings released: US$0.11 loss per share (vs US$0.048 loss in 1Q 2021)

Oncocyte Corporation Completes Validation of TheraSure™ Transplant Monitor Test

High number of new directors

Broadwood Capital Engages in Discussions with OncoCyte Corporation

OncoCyte Corporation has completed a Follow-on Equity Offering in the amount of $35.000001 million.

High number of new directors

OncoCyte Corporation to Report Q4, 2021 Results on Mar 10, 2022

OncoCyte Corporation Announces Peer-Reviewed Publication in Cancers Showing Utility of DetermaCNI™ Blood-Only Monitoring Test to Detect Recurrence Following Surgery in Epithelial Ovarian Cancer

Oncocyte Corporation Announces Results from DetermaIO™ Test

Third quarter 2021 earnings released: US$0.15 loss per share (vs US$0.10 loss in 3Q 2020)

High number of new directors

Broadwood Partners Engages in Discussions with OncoCyte Corporation

Oncocyte Corporation Announces Oral Presentation of New Data on Its DetermaIO Immunotherapy Response Test at the European Society for Medical Oncology Annual Meeting

Oncocyte Corporation Launches Nationwide, Prospective, Real-World Registry for Patients with Potentially Curable Early-Stage Lung Cancer

Second quarter 2021 earnings released: US$0.12 loss per share (vs US$0.14 loss in 2Q 2020)

High number of new directors

CEO, President & Director recently bought US$53k worth of stock

OncoCyte Corporation Announces Peer-Reviewed Publication of Data Assessing Use of DetermaIO™ to Identify Patients Likely to Benefit from Immunotherapy Across Multiple Tumor Types

Oncocyte Corporation Announces Formation of Medical Advisory Board

Oncocyte Corporation Announces Agreement with MultiPlan Network, Expanding Patient Access to Determarx™

OncoCyte Corporation to Report Q4, 2020 Results on Mar 16, 2021

OncoCyte Corporation has completed a Follow-on Equity Offering in the amount of $35.01 million.

OncoCyte Corporation (AMEX:OCX) entered into an agreement to acquire Chronix Biomedical, Inc. for $23.9 million.

Oncocyte Corporation to Present New Data At the IASLC 2020 World Conference on Lung Cancer

OncoCyte Corporation Enters into an Exclusive Sublicense Agreement in the PRC Territory

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento